Xtandi Better, Cheaper than Zytiga for Treatment of mCRPC, Study Suggests

Xtandi Better, Cheaper than Zytiga for Treatment of mCRPC, Study Suggests
Treating chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients with Xtandi (enzalutamide) leads to better survival outcomes and lower healthcare costs than Zytiga (abiraterone acetate), a study suggests. The findings were presented at the American Urological Association's 2019 Annual Meeting, May 3-6, in Chicago, in the study, "Survival Rates and Economic Outcomes in Chemotherapy-naive Metastatic Castrate Resistant Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide." While therapies that lower male sex hormones — required for prostate cancer to survive and grow — are a mainstay of therapy for advanced prostate cancer, most patients will acquire resistance to such approaches. This often happens because the receptor for these hormones, called the androgen receptor, becomes constantly active, even in the absence of androgens. Therapies that inhibit the androgen receptor — such as Pfizer and Astellas' Xtandi and Janssen's Zytiga — have largely improved the overall survival of prostate cancer patients, and are now approved for mCRPC patients in the U.S. and Europe. However, which treatment brings the most benefits or the lowest healthcare costs has not been addressed. In this study, researchers performed a retrospective study to compare the overall survival and healthcare costs associated with these two second-generation androgen receptor inhibitors. They examined data from 3,174 adult men with mCRPC who had not received chemotherapy for at least one year before starting treatment with either Xtandi or Zytiga. Patients had been treated between April 2014 and March 2017, and their data were recovered from the Veterans Health Administration (VHA) database. Overall, 1,945 patients, mean age 73,
Subscribe or to access all post and page content.